News & Updates

เรื่องของสมอง ทำไมต้อง ‘คาร์โนซีน’ และ ‘วิตามิน บี12’

Luspatercept transforming the management of β-thalassaemia

β-thalassaemia, an inherited haemoglobin disorder, affects approximately 1.5 percent of the global population, with 60,000 symptomatic individuals born annually, predominantly in low- and middle-income countries. [Orphanet J Rare Dis 2010;5:11]

What’s new, what’s hot in diabetes management: Snippets from ATTD-ASIA

ATTD-ASIA 2024, held recently in Singapore, was a huge success, with nearly 800 delegates from 49 countries gracing the event. ATTD-Asia 2024 chair, Professor Moshe Phillip, said the event brought together top diabetes experts to ensure patients can access the latest technologies and treatments for diabetes. MIMS Doctor reports highlights and snippets from the conference.

Video: Revolutionizing β-thalassemia Treatment

Dr Christopher Chin Keong Liam of Hospital Sultanah Aminah, Malaysia, shares his expertise on β-thalassemia and its treatment landscape, including clinical evidence for luspatercept in transfusion dependent or non-transfusion dependent β-thalassemia.

Podcasts@ATTD-ASIA: Experts share how CGM transforms diabetes care

Podcasts@ATTD-ASIA: Experts share how CGM transforms diabetes care

Nirmatrelvir-ritonavir efficacy and risk factors for COVID-19 hospitalization

The post-pandemic burden of COVID-19 remains significant in adults. Four studies from IDWeek 2024 highlight the benefits of nirmatrelvir-ritonavir (NMV/r) for high-risk adults with SARS-CoV-2 immunity and link chronic conditions to COVID-19 hospitalization. Identifying high-risk patients and using NMV/r in outpatient settings can reduce severe outcomes.

Clinical considerations for patients at high risk for progression to severe COVID-19

COVID-19 has not gone away. New contagious variants continue to be a leading cause of death, with underlying conditions still influencing the risk of COVID-19 hospitalizations, said Dr Ali Hassoun, Clinical Professor of Medicine and infectious disease specialist at Crestwood Medical Center, Huntsville, Alabama, US, who spoke at a Pfizer-sponsored session during IDWeek 2024.

Ropeginterferon alfa-2b supports a shift in polycythaemia vera treatment

Professor Jean-Jacques Kiladjian, Professor of Clinical Pharmacology, Consultant Haematologist, and head of the Clinical Investigation Centre of Hôpital Saint-Louis & Université Paris Cité in Paris, France, discusses the drawbacks of conventional therapy for PV, and how ropeginterferon alfa-2b may support a shift in treatment.

The role of ropeginterferon alfa-2b in the management of polycythaemia vera in SG

MIMS Oncology explores the current landscape of polycythaemia vera management in Singapore and the role of the newly launched ropeginterferon alfa-2b in improving patient outcomes. During an interview, Dr Dawn Mya, a leading haematologist practicing at Parkway Cancer Centre, Singapore, provides expert insights into the therapeutic potential of this novel treatment.

ESMO 2024 Kidney Cancer Puzzles: From Insights to Progress